Primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6 th birthday against diphtheria, tetanus, pertussis and invasive Haemophilus influenza type b infection.
This combined vaccine is indicated for adults as a booster of a previous vaccination for the simultaneous prevention of diphtheria tetanus and poliomyelitis.
Refer to the official recommendations for vaccination schedules.
This vaccine may be administered as a booster of a previous vaccination to children 6 or older in exceptional cases particularly in the case of a shortage of the diphtheria tetanus and poliovirus vaccine (DTPolio|) recommended in the vaccination schedule.
Pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7 th birthday against diphtheria, tetanus, whooping cugh, poliomyelitis and invasive Haemophilus influenza type b disease.
In ifants, three infectons are to be given intramuscularly at 2,4 and 6 months of age followed by a booster at 18 months of age.
Children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity.
Children who have had natural pertussis can continue to receive pertussis - containing vaccines.
Human immunodeficiency virus (HIV) infected persons HIV- infected individuals, both asymptomatic and symptomatic, should be immunized with Pediacel vaccine according to standart schedules.
Active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 4 years and over as a booster following primary immunization.
Adacel polio is not indicated for primary immunization.
Adacel polio is not indicated for treating diseases caused by B.pertussis, C.Diphtheriae or C.tetani or by poliomyelitis infections.
Is indicated for the primary immunization of infants at or above the age of 2 months and as a booster in children up to their 6 th birthday against diphtheria, tetanus and pertussis.
For the treatment of superficial transitional cell carcinoma (TCC) of the urinary bladder, regardless of antecedent intravecical treatment superficial TCC comprises the following: carcinoma in situ (CIS), papillary tumors limited to the mucosa (stage Ta), papillary tumors invoiving the lamina propria but not the muscle layer of the bladder (stage T1), or any combination thereof.
Immucyst is indicated for treatment and prophylaxis of primary or recurrent carcinoma insitu (CIS) of the urinary bladder and for prophylaxis following trans-urethral resection (TUR) of primary or rcurrent stage Ta and / or T1 papillary tumors.